Holen Sie sich die Stockscreener-App
2.94
7.84%
-0.25
Handel nachbörslich:
2.95
0.01
+0.34%
Vigil Neuroscience Inc Aktie (VIGL) Neueste Nachrichten
Citadel Advisors LLC Adjusts Position in Vigil Neuroscience Inc - GuruFocus.com
Vigil Neuroscience, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Deep Track Capital, LP Increases Stake in Vigil Neuroscience Inc - GuruFocus.com
Vigil Neuroscience to Present at Upcoming Investor Conferences - GlobeNewswire
Vigil Neuroscience Reports Third Quarter 2024 Financial Results and Provides Business UpdateOn November 7, 2024, Vigil Neuroscience, Inc. (NASDAQ: VIGL) released its financial results for the third quarter ended September 30, 2024. The company, dedic - Defense World
Vigil Neuroscience’s (VIGL) “Buy” Rating Reiterated at HC Wainwright - Defense World
Vigil Neuroscience (NASDAQ:VIGL) Price Target Raised to $24.00 - Defense World
Vigil Neuroscience (NASDAQ:VIGL) Given New $24.00 Price Target at Wedbush - MarketBeat
HC Wainwright Reiterates Buy Rating for Vigil Neuroscience (NASDAQ:VIGL) - MarketBeat
Vigil Neuroscience Advances Key Clinical Programs - TipRanks
Vigil Neuroscience Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
Vigil Neuroscience, Inc. (NASDAQ:VIGL) has caught the attention of institutional investors who hold a sizeable 41% stake - Yahoo Finance
Vigil Neuroscience Inc (VIGL) Quarterly 10-Q Report - Quartzy
Vigil Neuroscience to Present at Guggenheim Healthcare Innovation Conference - GlobeNewswire
abrdn plc Makes New $799,000 Investment in Vigil Neuroscience, Inc. (NASDAQ:VIGL) - MarketBeat
We Think Vigil Neuroscience (NASDAQ:VIGL) Needs To Drive Business Growth Carefully - Simply Wall St
Vigil Neuroscience retains stock target on TREM2 potential - Investing.com
Vigil Neuroscience retains stock target on TREM2 potential By Investing.com - Investing.com Australia
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Vigil Neuroscience, Inc. (NASDAQ: VIGL) - Victoria Advocate
Quanterix Welcomes Ivana Magovčević-Liebisch, Ph.D., J.D. to Board of Directors - BioSpace
Quanterix Appoints Ivana Magovčević-Liebisch to Board of Directors - citybiz
Point72 Asset Management L.P. Buys New Position in Vigil Neuroscience, Inc. (NASDAQ:VIGL) - Defense World
Point72 Asset Management L.P. Acquires New Position in Vigil Neuroscience, Inc. (NASDAQ:VIGL) - MarketBeat
Vigil Neuroscience, Inc. (NASDAQ:VIGL) Shares Purchased by Ensign Peak Advisors Inc - MarketBeat
Vigil Neuroscience, Inc. (NASDAQ:VIGL) Short Interest Down 20.3% in September - MarketBeat
Is Vigil Neuroscience (NASDAQ:VIGL) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Certified Advisory Corp Grows Stake in Vanguard Dividend Appreciation ETF (NYSEARCA:VIG) - Defense World
Vanguard Dividend Appreciation ETF (NYSEARCA:VIG) Shares Purchased by Harmony Asset Management LLC - Defense World
Evergreen Capital Management LLC Sells 380 Shares of Vanguard Dividend Appreciation ETF (NYSEARCA:VIG) - Defense World
Circle Wealth Management LLC Acquires 383 Shares of Vanguard Dividend Appreciation ETF (NYSEARCA:VIG) - Defense World
Garden State Investment Advisory Services LLC Acquires 743 Shares of Vanguard Dividend Appreciation ETF (NYSEARCA:VIG) - Defense World
VICOR 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Vicor CorporationVICR - Business Wire
INVESTOR DEADLINE MONDAY: Robbins Geller Rudman & Dowd LLP Announces that Vicor Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – VICR - ForexTV.com
Vigil Neuroscience shares maintain Outperform rating on positive FDA update - Investing.com
WCG Wealth Advisors LLC Has $3 Million Position in Vanguard Dividend Appreciation ETF (NYSEARCA:VIG) - Defense World
Bradley Foster & Sargent Inc. CT Cuts Position in Vanguard Dividend Appreciation ETF (NYSEARCA:VIG) - Defense World
1,275 Shares in Vanguard Dividend Appreciation ETF (NYSEARCA:VIG) Bought by One Capital Management LLC - Defense World
Vanguard Dividend Appreciation ETF (NYSEARCA:VIG) Shares Sold by ProVise Management Group LLC - Defense World
Vigil Neuroscience shares maintain Outperform rating on positive FDA update By Investing.com - Investing.com Australia
FDA lifts partial clinical hold on Vigil Neuroscience’s Phase I VG-3927 trial - Clinical Trials Arena
FDA lifts hold on Vigil Neuroscience's Alzheimer trial By Investing.com - Investing.com Canada
Vigil Neuroscience Announces FDA Has Removed Partial Clinical Hold on VG-3927 - ForexTV.com
Vigil stock gains as FDA removes partial hold (NASDAQ:VIGL) - Seeking Alpha
FDA lifts hold on Vigil Neuroscience's Alzheimer trial - Investing.com India
Vigil Neuroscience Advances Alzheimer’s Trial, Eyes 2025 Data - TipRanks
Vigil Neuroscience Says FDA Lifts Partial Hold Alzheimer's-Treatment Trial - MarketWatch
Vigil Neuroscience rises as FDA lifts partial hold on Alzheimer’s disease trial - XM
The Neuroscience Market Research Explores 2024: Advancing Brain Research and Therapeutics - WhaTech
Vigil Neuroscience to Present at Cantor Global Healthcare Conference - GlobeNewswire
Vigil Neuroscience, Inc. (NASDAQ:VIGL) Short Interest Update - MarketBeat
Vigil Neuroscience, Inc. (NASDAQ:VIGL) Short Interest Down 23.7% in August - Defense World
Vigil Neuroscience (NASDAQ:VIGL) Trading 5% Higher - MarketBeat
Small Neurodegenerative Disease-Focused Vigil Neuroscience Says Alzheimer's Candidate Shows Significant Impact On Disease Bimarker - AOL
Neurodegenerative Disorder Therapeutics Market Insights Discussed Regarding Size And Outlook 2024-2033 - WhaTech
A stock that deserves closer examination: Vigil Neuroscience Inc (VIGL) - US Post News
You might want to take a look at Vigil Neuroscience Inc (VIGL) now - SETE News
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):